SurModics Inc (SRDX)

[DewDiligence]

>The long terminal half-life (~5.6 days) suggests that injections of a therapeutic antibody in solution every 1 or 2 months may provide adequate concentrations without further formulation work....<

This finding has indeed been borne out. However, an injection every 1-2 months—or even every 3 months—is a lot of injections when you are talking about chronic treatment.

DNA’s original research was aimed at getting a drug to market, which required showing effiiacy only as far out as one year. But now DNA has hard data showing continued efficacy of Lucentis in the second year, and no one knows exactly how long therapy ought to be continued. Thus, the potential benefit of a slow-release formulation of Lucentis may be considerably greater than it was previously thought to be.